Merck announced Wednesday that it has secured the rights to an experimental weight-loss pill from Chinese drugmaker Hansoh Pharma in a deal value as much as $2 billion.

The oral drug has not yet been tested in humans, and Merck has not specified which diseases it plans to check the drug on first. Still, it increases the drug company's probabilities of capturing a slice of the booming obesity drug market, which some analysts expect to be value greater than $100 billion a 12 months by the early 2030s.

Several other drug manufacturers including Pfizer And Rocheare in search of to develop more practical obesity pills that may compete with the blockbuster injections from Novo Nordisk and Eli Lilly.

Under the agreement, Merck will receive the exclusive worldwide license to develop, manufacture and commercialize Hansoh Pharma's HS-10535, an experimental oral drug that targets a gut hormone called GLP-1. Novo Nordisks The popular weight reduction drug Wegovy and the diabetes drug Ozempic also goal GLP-1 to suppress appetite and regulate blood sugar.

Merck can pay Hansoh $112 million upfront for the rights to the drug, with the potential for a further $1.9 billion in milestone payments and royalties. in line with a press release.

Merck said its fourth-quarter results will include a pretax charge of $112 million, or 4 cents per share.

In the press release, Dean Li, president of Merck Research Laboratories, said the oral drug “has the potential to provide additional cardiometabolic benefits beyond weight reduction.”

Merck CEO Rob Davis said early last 12 months that the corporate was in search of GLP-1 treatments with advantages beyond weight reduction.

“I feel everyone recognizes that weight management is difficult to reimburse. But in the event you can show cardiovascular outcomes, in the event you can show diabetes outcomes, which you're beginning to see data for, in the event you can see advantages in fatty liver disease…” “That's an area where we expect there's opportunity,” he said at the time at a conference.

This is the latest transaction involving experimental GLP-1 drugs from China. AstraZeneca Last year, Chinese company Eccogene licensed its experimental oral drug, which is now in mid-stage development.

Merck on Thursday reported Third-quarter sales and adjusted profit beat expectations as the corporate posted strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.

But Merck's vaccine, which prevents cancer attributable to HPV, essentially the most common sexually transmitted infection within the U.S., posted one other quarter of lower-than-expected sales. Sales of the Gardasil vaccine fell 11% in comparison with the identical period last 12 months.

The pharmaceutical giant lowered its full-year revenue forecast to a spread of $63.6 billion to $64.1 billion from a previous forecast of $63.4 billion to $64.4 billion.

Merck also cut its adjusted earnings forecast to a spread of $7.72 to $7.77 per share, from a previous forecast of $7.94 to $8.04 per share. This updated outlook reflects a one-time charge of 24 cents per share related to business development agreements with Curon Biopharmaceutical and Daiichi Sankyo.

Shares of Merck fell nearly 3% on Thursday.

Here's what Merck reported for third quarter in comparison with Wall Street expectations based on an analyst survey by LSEG:

• Earnings per share: $1.57 adjusted vs. $1.50 expected
• Revenue: $16.66 billion versus expected $16.46 billion

Merck posted third-quarter net income of $3.16 billion, or $1.24 per share. In comparison, net income within the year-ago period was $4.75 billion, or $1.86 per share.

Excluding acquisition and restructuring costs, Merck earned $1.57 per share within the three-month period.

The company reported third-quarter revenue of $16.66 billion, up 4% from the identical period last 12 months.

The findings come as Merck is making significant progress in preparing for Keytruda's patent expiration in 2028. Losing exclusive rights to the drug will likely result in a decline in sales and force the corporate to attract revenue from other sources.

Merck has a handful of latest deals and major drug launches in its books that can help it offset those losses. This includes Winrevair, a drug approved within the US in March to treat a progressive and life-threatening lung disease.

And Capvaxive, a vaccine designed to guard adults against a bacteria called pneumococcus that could cause serious illness and lung infections, was approved within the U.S. in June.

The company's pipeline of late-stage drugs has nearly tripled up to now three years or so to greater than 20 unique products, Merck CEO Rob Davis said during a conference call Thursday.

He said this may result in a major variety of drug and vaccine launches over the following five years, most of which have “blockbuster-plus potential”. Blockbuster drugs generate a minimum of $1 billion in annual sales.

Merck's pharmaceutical division, which develops a big selection of medication, posted third-quarter sales of $14.94 billion, up 5% from the identical period last 12 months.

The company's immunotherapy drug Keytruda posted revenue of $7.43 billion within the quarter, up 17% from the year-ago period. Analysts had expected Keytruda sales of $7.33 billion, based on StreetAccount estimates.

This increase was as a result of higher uptake of Keytruda in early-stage cancers and powerful demand for the drug against metastatic cancers that spread to other parts of the body.

Gardasil had sales of $2.31 billion. Merck said the decline was primarily as a result of lower demand in China in comparison with the identical period last 12 months. This was partially offset by higher sales within the US

That's below the $2.51 billion analysts were expecting, based on StreetAccount.

Davis said the corporate is “heavily focused” on the China market and is moving forward with its commercialization partner Zhifei to extend Gardasil promotional and patient education efforts.

“We expect these efforts will result in increased patient activation and demand, but as we said, this will take time,” Davis said.

Davis said Merck was confident in Gardasil's long-term prospects on condition that lower than 10% of the eligible population worldwide has been vaccinated. The company expects to succeed in its goal of world Gardasil sales of $11 billion by 2030.

After approval in March, Winrevair reported third-quarter revenue of $149 million. Analysts had expected sales of $127 million.

About 1,700 people received a Winrevair prescription through the quarter, bringing the full number of latest patient prescriptions for the reason that drug's launch to three,700, Merck CFO Caroline Litchfield said through the call. The company estimates that about 80% of those patients receive the actual drug.

The company's type 2 diabetes drug Januvia posted sales of $482 million, down 42% from the identical period last 12 months. Merck said the decline was primarily as a result of lower drug prices within the U.S. in addition to competition from generics in several countries.

According to StreetAccount, analysts had expected sales of $610 million.

Januvia is one in every of 10 drugs which are the topic of ongoing Medicare pricing negotiations, a policy geared toward making expensive drugs more cost-effective for seniors. Those price talks, a key provision of President Joe Biden's Inflation Reduction Act, will end in early August.

Sales of Merck's antiviral Covid pill Lagevrio also fell 40% to $383 million within the quarter.

However, based on StreetAccount, this beat analysts' expectations with revenue of $124.2 million.

Merck's animal health division, which develops vaccines and medications for dogs, cats and cattle, posted third-quarter sales of $1.49 billion. This is 6% greater than in the identical period last 12 months and is barely above the expectations of analysts surveyed by StreetAccount.

Merck On Thursday it said experimental recording The vaccine, designed to guard infants against respiratory syncytial virus, showed positive leads to a mid- to late-stage trial, bringing the corporate one step closer to applying for approval of the vaccine.

The pharmaceutical giant could emerge as a brand new competitor available in the market for treatments against RSV, which results in this Thousands Deaths amongst older Americans and a whole lot of deaths amongst young children every year. Complications from the virus are essentially the most common reason behind hospitalization in newborns, making Merck's drug a priceless latest treatment option if approved.

According to a press release, Merck plans to debate the study data with regulators worldwide with the goal of constructing the treatment available to infants as early because the 2025 to 2026 RSV season.

The study examined the security and effectiveness of a single dose of the treatment clesrovimab in healthy premature and full-term infants entering their first RSV season. Merck presented the outcomes on the IDWeek medical conference in Los Angeles.

Merck said the treatment reduced RSV-related hospitalizations by greater than 84% and hospitalizations resulting from lower respiratory tract infections by 90% in comparison with a placebo in infants as young as five months old. Clesrovimab also reduced lower respiratory tract infections requiring medical attention by greater than 60% over five months in comparison with a placebo.

RSV is a standard reason behind Lower respiratory tract infections equivalent to pneumonia. The results were consistent at each five and 6 months of the study, Merck said.

The frequency of antagonistic and serious negative effects was similar between patients who received Merck's shot and those that took placebo within the study. The company added that there have been no treatment-related or RSV-related deaths within the study.

“These promising results, showing a lower incidence of RSV disease, including hospitalizations, highlight the potential for clesrovimab to play an important role in alleviating the ongoing RSV burden for infants and their families,” Dr. Octavio Ramilo, chairman of the Division of Infectious Diseases at St. Jude's Children's Research Hospital, said the Merck press release. Ramilo can be involved within the court proceedings as an investigator.

Merck's clesrovimab could potentially compete with an identical treatment Sanofi And AstraZeneca called Beyfortus, which was briefly supply across the country last RSV season resulting from unprecedented demand. Both are monoclonal antibodies that release antibodies directly into the bloodstream, providing immediate protection.

However, Merck's treatment will be given to infants no matter their weight, which the corporate says could provide more convenient dosing. Meanwhile, the beneficial dosage of Beyfortus relies on an infant's body weight.

A Sanofi spokesman said the dosage of Beyfortus was “carefully selected as part of our clinical development and reflects the correct dosage for each baby,” with two different dosages depending on whether or not they are kind of than five kilograms, or about 11 kilos weighs. The implementation of those two doses was “effectively managed by providers” through the last RSV season, the spokesperson added.

Sanofi expects the US market to have sufficient Beyfortus inventory through the current RSV season, which usually begins in the autumn and lasts through the spring.

Last 12 months, Pfizer has launched an RSV vaccine that’s given to expectant moms who can pass the protection on to their fetuses.

Merck reported second-quarter revenue and adjusted profit on Tuesday that beat Wall Street expectations, reflecting strong sales of its hit cancer drug Keytruda, in addition to other treatments in its oncology and vaccines portfolio and a newly launched cardiovascular drug.

The pharmaceutical giant also raised its full-year revenue forecast to $63.4 billion to $64.4 billion as demand for key products, particularly cancer drugs, has increased. That's only barely higher than the $63.1 billion to $64.3 billion forecast the corporate gave in April.

Merck lowered its adjusted earnings forecast to a variety of $7.94 to $8.04 per share, from a previous forecast of $8.53 to $8.65 per share. This updated forecast takes under consideration one-time costs of 26 cents and 51 cents per share for the acquisitions of Harpoon therapeutics And EyeBiosaid Merck.

Nevertheless, the corporate's shares lost greater than 6 percent on Tuesday.

Here is what Merck is doing for the second quarter in comparison with Wall Street expectations based on an analyst survey conducted by LSEG:

• Earnings per share: USD 2.28 adjusted versus USD 2.15 expected
• Revenue: $16.11 billion in comparison with expected $15.84 billion

The pharmaceutical company reported a net profit of $5.46 billion, or $2.14 per share, within the second quarter. In the identical period last 12 months, the corporate reported a net lack of $5.98 billion, or $2.35 per share. This also included costs related to the acquisition of Prometheus Biosciences.

Excluding acquisition and restructuring costs, the corporate earned $2.28 per share within the three-month period.

Merck reported sales of $16.11 billion for the quarter, up 7% from the identical period last 12 months.

The results come at a time when Merck is preparing to offset losses from the expiration of the Keytruda patent in 2028 by signing some recent contracts and bringing key medicines to market.

These include Winrevair, a drug approved within the United States in March to treat a progressive and life-threatening lung disease. Some analysts estimate that global sales of Winrevair could reach $5 billion by 2030.

It also includes Capvaxiva vaccine to guard adults against a bacterium known equivalent to pneumococci, which might cause serious illness and lung infections. The vaccine was approved within the US last month.

Merck's pharmaceutical division posted sales of $14.41 billion within the second quarter, 7 percent greater than in the identical period last 12 months. The division develops a big selection of medication for various disease areas.

The company's immunotherapy drug Keytruda generated sales of $7.27 billion within the quarter, up 16 percent from the identical period last 12 months. Analysts had expected sales of $7.12 billion for Keytruda, in line with estimates from StreetAccount.

The increase was as a result of increased use of Keytruda in early-stage cancer and powerful demand in metastatic cancer, which spreads to other parts of the body, the corporate's chief financial officer, Caroline Litchfield, said during a conference call on Tuesday.

Sales of Gardasil, a vaccine to forestall HPV cancer, probably the most common sexually transmitted infection within the United States, remained virtually unchanged.

Gardasil posted sales of $2.48 billion, up just 1% from the second quarter of 2023. Merck said growth was driven by higher prices within the U.S. but was held back by lower sales in China as a result of delivery timing.

“As soon as we know more, we will evaluate future deliveries to our partner and work to restore their inventory to more normal levels,” Litchfield said.

According to StreetAccount, segment results were barely below the $2.51 billion expected by analysts.

Winrevair reported second-quarter sales of $70 million following its approval in March. Analysts had expected the drug to generate sales of $59.4 million.

Merck estimates that about 40 percent of Winrevair sales are for doses given to U.S. patients, with the remainder coming from distributors build up inventory of the drug, Litchfield said. She noted that greater than 1,000 patients began Winrevair within the second quarter, largely as a result of prescriptions filled in April and May.

Meanwhile, type 2 diabetes drug Januvia posted sales of $629 million, down 27 percent from the identical period last 12 months. Merck said the decline was mainly as a result of lower demand and lower prices for the drug, together with competition from generics in several countries.

Januvia is considered one of 10 drugs which might be the topic of ongoing Medicare price negotiations, a policy designed to make expensive drugs more cost-effective for seniors. Those price negotiations, a key provision of President Joe Biden's inflation-fighting bill, end in early August.

Sales of Merck's antiviral Covid pill Lagevrio also fell, by 46% to $110 million within the quarter, but that also beat analysts' expectations of sales of $81.5 million, in line with StreetAccount.

Merck's animal health division, which develops vaccines and medicines for dogs, cats and cattle, reported second-quarter sales of $1.48 billion, up 2 percent from the identical period last 12 months and barely lower than analysts surveyed by StreetAccount had expected.

The Food and Drug Administration on Monday approved MerckThe recent vaccine is meant to guard adults from a bacterium known reminiscent of pneumococci, which may cause serious illness and a lung infection called pneumonia, the drugmaker said.

Merck’s shot, called Capvaxivspecifically protects against 21 strains of those bacteria and thus prevents a severe type of Pneumococcal disease which may spread to other parts of the body and result in pneumonia. It is the primary pneumococcal conjugate vaccine specifically developed for adults and is designed to supply broader protection than the available recordings in the marketplace, in accordance with the drug manufacturer.

Healthy adults can develop pneumococcal disease, but older patients and people with chronic or immunocompromised conditions are at higher risk for the disease, particularly the more severe or so-called “invasive” form.

Invasive pneumococcal disease can result in meningitis, an infection that causes inflammation in the realm across the brain and spinal cord, in addition to an infection within the bloodstream called bacteremia.

“If you have chronic lung disease or even asthma, you're at a higher risk of getting pneumococcus and then being hospitalized and losing your job,” said Heather Platt, head of Merck's product development team for the newly approved vaccine, in an interview with CNBC. “These are things that have a real impact on the quality of life of adults and children.”

About 150,000 adults within the U.S. are hospitalized with pneumococcal pneumonia annually, Platt said.. The mortality rate for the more severe type of the disease is highest in adults over 50, Merck said in a release In December.

Even after FDA approval, the corporate's single-dose vaccine won’t yet reach patients. An advisory panel of the Centers for Disease Control and Prevention will meet on June 27 to debate who must be eligible for the vaccination.

Platt said Merck will support the committee's decision and is prepared to supply the vaccine by late summer.

Some analysts see Capvaxive as a key growth driver for Merck, which is preparing to offset losses from its successful cancer drug Keytruda, which is able to lose its exclusivity within the U.S. in 2028.

The marketplace for pneumococcal conjugate vaccines is currently value around $7 billion and will grow to over $10 billion in the following few years, in accordance with a note published in November by analysts at Cantor Fitzgerald.

Merck's newly approved vaccine could increase its competitive advantage on this field, which incorporates drug manufacturers PfizerMerck currently markets two Pneumococcal vaccinationsbut neither is specifically designed for adults. For example, the prevailing vaccine from Vaxneuvance approved within the USA for patients aged 6 weeks and older.

Pfizer's pneumococcal vaccine Prevnar 20 is currently the market leader in adults, but Merck expects its recent vaccine to capture the biggest market share in adults, Platt said.

“We expect rapid adoption of Capvaxive,” she said, adding that the corporate was confident the vaccine data would “really resonate” with doctors and policymakers.

Merck's pneumococcal vaccine protects against eight strains of bacteria not included in some other approved vaccine against the disease. These eight strains account for about 30% of cases of invasive pneumococcal disease in patients ages 65 and older, in accordance with a Merck press release, citing CDC data from 2018 to 2021.

The 21 strains included in Merck's vaccine are liable for about 85% of cases of invasive pneumococcal disease in adults ages 65 and older, Merck said, citing CDC data. Meanwhile, Pfizer's Prevnar targets strains which might be liable for only about 51% of cases in that age group, in accordance with the identical CDC data.

The FDA's approval is predicated partially on Merck's late-stage STRIDE-3 trial, which compared the vaccine to Pfizer's Prevnar 20 in adults 18 years of age and older who had not previously received pneumococcal vaccination.